echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Starting next month, the designated pharmacies in this area will sell medical insurance drugs at a price limit

    Starting next month, the designated pharmacies in this area will sell medical insurance drugs at a price limit

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on the Publication of the Operational Measures for Drug Price Management of Designated Pharmacies in this City" (hereinafter referred to as the "Notice"), which will be officially implemented on November 1
    .
    The notice shows that designated pharmacies selling medical insurance catalog drugs must upload retail price information through the "Shanghai Pharmaceutical Purchasing Service and Supervision Information System" (hereinafter referred to as the Sunshine Platform), and the bargaining prices of related drugs at designated medical institutions can be inquired on the platform each drugstore sales retail prices of medicines and so on
    .
    It should be noted that the notice also requires designated pharmacies to upload the retail price and fill in the effective date of the price according to the information pushed by the Sunshine platform and the "red and yellow prompt line", combined with the relevant provisions of the designated pharmacy's medical insurance service agreement
    .
    In addition, the pharmacy will also establish a price "red-yellow line" monitoring and early warning mechanism based on the relevant provisions of the designated pharmacy medical insurance service agreement, referring to the prices of drugs purchased by designated medical institutions with the same product regulations or the same generic name as the company
    .
    In this regard, the industry believes that the notice will be a major challenge for designated pharmacies whose sales of medical insurance drugs account for about 50%.
    The prices of their drugs may be further reduced, and they will be subject to stricter regulatory control.
    Its gross profit is expected to be Received a lot of shock
    .
    However, for patients, this will be a big plus
    .
    In fact, in recent years, with the reform of medical policies and the implementation of the national inclusive policy, the number of retail pharmacies in various localities has continued to increase, which has indeed brought convenience and benefits to the public for medical treatment, medical treatment, and drug purchase; but at the same time, competition in the market Under the circumstances, some retail pharmacies have also begun to appear in a state of confusion in terms of drug prices
    .
    The phenomenon that the same drug is sold at several prices in several pharmacies not far away is common .
    Therefore, in recent years, the state has successively introduced a series of institutional measures to deepen the reform of pharmaceutical prices and promote the formation of reasonable prices, and it is clear that it is necessary to increase the monitoring of pharmaceutical prices and the release of information
    .
    In fact, under the background that the country is vigorously advancing and doing a good job in the current drug price management work, in addition to Shanghai, many provinces and cities have also introduced related designated pharmacies "price limit" and regulatory documents.

    .
    For example, in September this year, the Guangdong Provincial Medical Insurance Bureau, in conjunction with the Guangdong Provincial Health Commission and the Provincial Drug Administration, issued the "Implementation Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for Drugs in National Medical Insurance Negotiations" (hereinafter referred to as the "Guiding Opinions"), It is clear that medical insurance designated retail pharmacies will be included in the scope of national medical insurance negotiation drugs (hereinafter referred to as negotiated drugs) supply guarantees, and together with medical insurance designated medical institutions, a "dual channel" for negotiating drug supply guarantees will be formed
    .
    The drugs included in the "dual channel" will implement a unified medical insurance payment standard and price policy at designated medical institutions and "dual channel" pharmacies
    .
    In addition, as early as 2019, the Xianning Medical Security Bureau of Hubei Province issued an announcement on the highest retail price of 100 commonly used drugs in Xianning urban medical insurance designated retail pharmacies, 15 yuan a box of candesartan cilexetil tablets (reported Junning) dropped to 9.
    9 yuan, and Shuangzuotai suppository dropped from 10.
    08 yuan to 6.
    1 yuan.
    .
    .
    The average drop of these 100 commonly used drugs was 6.
    01%, and the drop of individual products with high varieties even reached 46.
    67%, and the price reduction effect was obvious
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.